Investigating Patient Satisfaction With Oral Anti-cancer Treatment in Patients With Hormone-receptor Positive, HER2-receptor Negative, Advanced Breast Cancer
Recurrence or progression following a non-steroidal aromatase inhibitor
Able to swallow and retain oral medication
Eastern Cooperative Oncology Group (ECOG) Performance Status 0, 1 or 2
You may not be if
Patients who are not able to understand Dutch or French
Symptomatic visceral metastatic disease
Patients who have taken an investigational drug within 28 days or 5 half-lives, whichever is shorter, prior to recruitment
Current use of a prohibited medication as described in the SPC
Any serious or unstable pre-existing medical conditions, psychiatric disorders, or other conditions that could interfere with the subject's safety, obtaining informed consent, or compliance with study procedure
Hypersensitivity to the active substances or to any of the excipients
Clareo Health | Investigating Patient Satisfaction With Oral Anti-cancer Treatment in Patients With Hormone-receptor Positive, HER2-receptor Negative, Advanced Breast Cancer
